This week, Kanchan Singh, Siyu FENG, PhD, and Nadege Gitego will be presenting posters at The Fifth RAS Initiative Symposium (https://lnkd.in/gErqiTdg). Each will share data from one of our three lead programs seeking to develop new therapies to treat RAS-dependent cancers: direct dual KRASG12C mutant (ON/OFF) inhibitor BBO-8520, PI3Kα:RAS breaker BBO-10203, and pan-KRAS inhibitor BBO-11818. Learn more about us and our portfolio: https://lnkd.in/gYpPs_fq
BridgeBio Oncology Therapeutics
Biotechnology Research
South San Francisco, CA 1,403 followers
About us
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company advancing a next generation pipeline of novel small molecule therapeutics targeting RAS and PI3K malignancies. Initially formed as a subsidiary of BridgeBio, BridgeBio Oncology Therapeutics completed a $200M private financing with external investors in 2024 with the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors.
- Website
-
www.bridgebiooncology.com
External link for BridgeBio Oncology Therapeutics
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- South San Francisco, CA
- Type
- Privately Held
Locations
-
Primary
1 Corporate Drive
South San Francisco, CA 94080, US
Employees at BridgeBio Oncology Therapeutics
Updates
-
This week, BBOT’s Chief Scientific Officer Pedro J. Beltran will be giving a talk at The Fifth RAS Initiative Symposium (https://lnkd.in/gErqiTdg), where he will provide an overview of BBO-10203: our first-in-class PI3Kα:RAS breaker designed to inhibit RAS-driven PI3Kα/AKT signaling in tumors while avoiding hyperglycemia, and expected to enter the clinic later this year. Learn more about this and other programs in our portfolio: https://lnkd.in/gYpPs_fq
-
BBOT is pleased to welcome Yong (Ben) Ben as our first Chief Medical and Development Officer! Dr. Ben brings over 25 years of experience in R&D across the entire lifecycle of drug development, from early- to late-stage and through commercialization. He has been instrumental in the approval of more than 10 molecules in over 20 indications, covering various modalities including small molecules, biologics, and antibody-drug conjugates (ADCs). In this new role, Dr. Ben will oversee BBOT’s ongoing clinical programs, driving the development and delivery of new therapies for cancer patients, including BBO-8520, BBO-10203, and BBO-11818. We are thrilled to have him join our team, and look forward to working together to bring new treatments to patients in need.
-
Today, we have announced that the first patient has been dosed in our Phase 1 ONKORAS-101 trial for the study of BBO-8520 for those with non-small cell #lungcancer. Read more: https://lnkd.in/d52iWgMU
-
We're thrilled to introduce BridgeBio Oncology Therapeutics (BBOT)! We’re on a mission to advance a next generation pipeline of novel #smallmolecule therapeutics targeting RAS and PI3K malignancies. Led by Eli Wallace, Ph.D., as chief executive officer and Pedro J. Beltran, Ph.D., as chief scientific officer, we're looking forward to advancing three initial programs with the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. Read today's full announcement below.